美国波士顿儿童医院Adrienne G. Randolph团队研究了儿童多系统炎症综合征的初步治疗方案和效果。这一研究成果于2021年6月16日发表在《新英格兰医学杂志》上。
Title: Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Author: Mary Beth F. Son, M.D.,, Nancy Murray, M.Sc.,, Kevin Friedman, M.D.,, Cameron C. Young,, Margaret M. Newhams, M.P.H.,, Leora R. Feldstein, Ph.D.,, Laura L. Loftis, M.D.,, Keiko M. Tarquinio, M.D.,, Aalok R. Singh, M.D.,, Sabrina M. Heidemann, M.D.,, Vijaya L. Soma, M.D.,, Becky J. Riggs, M.D.,, Julie C. Fitzgerald, M.D.,, Michele Kong, M.D.,, Sule Doymaz, M.D.,, John S. Giuliano, Jr., M.D.,, Michael A. Keenaghan, M.D.,, Janet R. Hume, M.D.,, Charlotte V. Hobbs, M.D.,, Jennifer E. Schuster, M.D.,, Katharine N. Clouser, M.D.,, Mark W. Hall, M.D.,, Lincoln S. Smith, M.D.,, Steven M. Horwitz, M.D.,, Stephanie P. Schwartz, M.D.,, Katherine Irby, M.D.,, Tamara T. Bradford, M.D.,, Aline B. Maddux, M.D.,, Christopher J. Babbitt, M.D.,, Courtney M. Rowan, M.D.,, Gwenn E. McLaughlin, M.D.,, Phoebe H. Yager, M.D.,, Mia Maamari, M.D.,, Elizabeth H. Mack, M.D.,, Christopher L. Carroll, M.D.,, Vicki L. Montgomery, M.D.,, Natasha B. Halasa, M.D.,, Natalie Z. Cvijanovich, M.D.,, Bria M. Coates, M.D.,, Charles E. Rose, Ph.D.,, Jane W. Newburger, M.D., M.P.H.,, Manish M. Patel, M.D.,, and Adrienne G. Randolph, M.D.
The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.
We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2.
A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score–matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score–matched analysis.
Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.